Compare · NVO vs STSA
NVO vs STSA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Satsuma Pharmaceuticals Inc. (STSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and STSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 1383.9x STSA ($159.2M).
- NVO has hit the wire 5 times in the past 4 weeks while STSA has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 2 for STSA).
- Company
- Novo Nordisk A/S
- Satsuma Pharmaceuticals Inc.
- Price
- $41.18+6.93%
- $1.09-2.68%
- Market cap
- $220.35B
- $159.2M
- 1M return
- +13.32%
- -
- 1Y return
- -34.24%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Satsuma Pharmaceuticals Inc.
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. Its lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in ASCEND Phase III clinical trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S
Latest STSA
- SEC Form 15-12G filed by Satsuma Pharmaceuticals Inc.
- Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society's 65th Annual Scientific Meeting
- SEC Form 4 filed by Ra Capital Management, L.P.
- SEC Form SC 13D/A filed by Satsuma Pharmaceuticals Inc. (Amendment)
- Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
- SEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.
- SEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.
- SEC Form EFFECT filed by Satsuma Pharmaceuticals Inc.
- SEC Form 4 filed by O'Neil Thomas P.
- SEC Form 4 filed by Shah Rajeev M.